<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-RAVF0C4O/7c69fc04-4ef6-4971-a78f-b581db418221/PDF"><dcterms:extent>9754 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-RAVF0C4O/07e05be3-23d2-4ddf-b5e6-e14ee249e2a6/TEXT"><dcterms:extent>23 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1992-2025"><edm:begin xml:lang="en">1992</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-RAVF0C4O"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:SPR-WQVGMCSC" /><dcterms:issued>2019</dcterms:issued><dc:creator>Klar, Helena</dc:creator><dc:creator>Košnik, Mitja</dc:creator><dc:creator>Sotošek, Nika</dc:creator><dc:creator>Šelb, Julij</dc:creator><dc:format xml:lang="sl">letnik:28</dc:format><dc:format xml:lang="sl">številka:iss. 3</dc:format><dc:format xml:lang="sl">str. 97-101</dc:format><dc:identifier>ISSN:1581-2979</dc:identifier><dc:identifier>COBISSID_HOST:2048615793</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-RAVF0C4O</dc:identifier><dc:language>en</dc:language><dc:publisher xml:lang="sl">Dermatovenerologic Society of Slovenia</dc:publisher><dcterms:isPartOf xml:lang="sl">Acta dermatovenerologica Alpina, Pannonica et Adriatica</dcterms:isPartOf><dc:subject xml:lang="sl">Adverse effects</dc:subject><dc:subject xml:lang="sl">Anafilaksija</dc:subject><dc:subject xml:lang="sl">Anaphylaxis</dc:subject><dc:subject xml:lang="sl">Anti-inflammatory agents, non-steroidal</dc:subject><dc:subject xml:lang="sl">Diclofenac</dc:subject><dc:subject xml:lang="sl">Diklofenak</dc:subject><dc:subject xml:lang="sl">Drug hypersensitivity</dc:subject><dc:subject xml:lang="sl">Drug-related side effects and adverse reactions</dc:subject><dc:subject xml:lang="sl">Immunologic tests</dc:subject><dc:subject xml:lang="sl">Imunološki testi</dc:subject><dc:subject xml:lang="sl">Nesteroidna protivnetna sredstva</dc:subject><dc:subject xml:lang="en">oral provocation test</dc:subject><dc:subject xml:lang="sl">oralni provokacijski test</dc:subject><dc:subject xml:lang="sl">Pirazoloni</dc:subject><dc:subject xml:lang="sl">Preobčutljivost za zdravila</dc:subject><dc:subject xml:lang="sl">Pyrazolones</dc:subject><dc:subject xml:lang="sl">Stranski in škodljivi učinki zdravil</dc:subject><dc:subject xml:lang="sl">Škodljivi učinki</dc:subject><dcterms:temporal rdf:resource="1992-2025" /><dc:title xml:lang="sl">Selective hypersensitivity to a single nonsteroidal anti-inflammatory drug|</dc:title><dc:description xml:lang="sl">Introduction: The aim of the study was to explore the frequency and the clinical and diagnostic characteristics of a single nonsteroidal anti-inflammatory drug-induced hypersensitivity (SNIUAA) subgroup. Methods: In the hospital information system we identified patients who performed the oral provocation test (OPT) with analgesics between 2004 and 2016. We divided patients into phenotype groups based on clinical history and OPT results. Results: Altogether, 248 patients (44.3% of phenotyped patients) were diagnosed with SNIUAA. The most common offending drug in SNIUAA was diclofenac (52.4%), followed by pyrazolones (30.7%). In the group with selective diclofenac hypersensitivity, there was a larger percentage (40.0%) of patients with anaphylaxis. Compared to other phenotypes, significantly fewer patients had OPT performed with the suspected drug in SINUAA; however, in 69.4% of patients in this group, OPT with acetylsalicylic acid was performed. Conclusions: SNIUAA was the most common phenotype of nonsteroidal anti-inflammatory drug hypersensitivity in our cohort. Diclofenac was the most common cause of the hypersensitivity reaction and also the most common cause of anaphylactic reaction. In the group of patients with a positive history after taking diclofenac or pyrazolone, fewer OPTs with the suspected drug were performed, but more often OPT with aspirin to prove that hypersensitivity is selective</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-RAVF0C4O"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-RAVF0C4O" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-RAVF0C4O/7c69fc04-4ef6-4971-a78f-b581db418221/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Združenje slovenskih dermatovenerologov</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-RAVF0C4O/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-RAVF0C4O" /></ore:Aggregation></rdf:RDF>